Phase II study of 5-azacytidine in sarcomas of bone.
Eight patients with osteogenic sarcoma and seven patients with Ewing's sarcoma, all with advanced metastatic disease refractory to conventional therapy, were treated with 5-azacytidine (NSC-102816) intravenously at a dosage of 150 mg/m2 in three divided doses daily X 5 days. The courses were repeated q 4 weeks and the dosage was escalated to 200 mg/m2/day, as tolerated. Fourteen patients were evaluable for response. Major toxicities wee hematologic and gastrointestinal. 5-azacytidine had no demonstrable antitumor activity.
D000293:Adolescent; D000328:Adult; D001374:Azacitidine / Q000008:administration & dosage* / Q000009:adverse effects; D001859:Bone Neoplasms / Q000188:drug therapy*; D004334:Drug Administration Schedule; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007958:Leukocyte Count; D008297:Male; D009362:Neoplasm Metastasis; D009503:Neutropenia / Q000139:chemically induced; D012516:Osteosarcoma / Q000188:drug therapy*; D010976:Platelet Count; D012512:Sarcoma, Ewing / Q000188:drug therapy*; D013921:Thrombocytopenia / Q000139:chemically induced
D001374:Azacitidine